Abstract
Kidney transplantation offers patients with end-stage renal disease the greatest potential for increased longevity and enhanced quality of life; however, the demand for kidneys far exceeds the available supply. This has led to an increase in the number of people on waiting lists and an increase in waiting time. In the US, the overall median wait time was 2.85 years in 2004. The projected median waiting time for adult patients awaiting a deceased donor kidney in 2006 is 4.58 years. The renal transplant community has pursued multiple avenues in an attempt to increase the donor pool, but this remains a major challenge. In the last decade, the number of live donor kidney transplants performed in the US and Canada has doubled and represents just over 40% of all donor kidneys. Among deceased donor kidneys, the largest percentage increases were seen in expanded criteria donor and donation after cardiac death kidneys. In the last decade, the age distribution among donors, and among patients on waiting lists or receiving a renal transplant, has shifted towards older age groups. There have been dramatic shifts in baseline immunosuppression with increased usage of induction agents and the nearly universal replacement of azathioprine by mycophenolate. Additionally, tacrolimus use has increased from 13% to 79% at discharge, while ciclosporin (cyclosporine) use has fallen from 76% to 15%. Although 1-year graft survival rates are excellent, only modest improvements have been observed in long-term graft survival rates in the last decade. Thus, efforts have shifted from improving early graft outcomes to altering the natural course of late graft failure. Death of transplant recipients from cardiovascular disease, infection and cancer remains an important limitation in kidney transplantation. Continued success in kidney transplantation will require increased numbers of donors, both living and deceased, as well as reduction in the primary causes of late transplant loss, namely premature patient death with a functioning graft and chronic allograft nephropathy.
MeSH Terms
Age Factors
Canada
Graft Survival
Humans
Immunosuppressive Agents/therapeutic use
Kidney Failure, Chronic/therapy
Kidney Transplantation/trends
Survival Rate
Time Factors
Tissue and Organ Procurement
United States
Waiting Lists
Chemicals
Immunosuppressive Agents
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Knoll Greg
Division of Nephrology, University of Ottawa, Ottawa, Ontario, Canada.
[email protected]
References (24)
24 references, click to expand
-
Expanded criteria donors: process and outcomes.
Semin Dial. 2005 Nov-Dec;18(6):463-8
PMID: 16398707
-
Racial disparities in living kidney donation: is there a lack of willing donors or an excess of medically unsuitable candidates?
Transplantation. 2006 Oct 15;82(7):876-81
PMID: 17038900
-
Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies.
Clin Transplant. 2004 Aug;18(4):446-9
PMID: 15233824
-
Sirolimus for Kaposi's sarcoma in renal-transplant recipients.
N Engl J Med. 2005 Mar 31;352(13):1317-23
PMID: 15800227
-
Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment.
Transpl Int. 2003 Mar;16(3):202-6
PMID: 12664217
-
Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation.
Am J Transplant. 2007 Mar;7(3):586-94
PMID: 17229066
-
ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends.
Nephrol Dial Transplant. 2005 Dec;20(12):2587-93
PMID: 16204281
-
A study of the quality of life and cost-utility of renal transplantation.
Kidney Int. 1996 Jul;50(1):235-42
PMID: 8807593
-
Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy.
Transplantation. 2002 May 27;73(10):1565-72
PMID: 12042641
-
Long-term patient survival: strategies to improve overall health.
Am J Kidney Dis. 2006 Apr;47(4 Suppl 2):S65-85
PMID: 16567242
-
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial.
Lancet. 2003 Jun 14;361(9374):2024-31
PMID: 12814712
-
Cancer after kidney transplantation in the United States.
Am J Transplant. 2004 Jun;4(6):905-13
PMID: 15147424
-
Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.
Cochrane Database Syst Rev. 2006 Apr 19;(2):CD004290
PMID: 16625599
-
Cancer incidence before and after kidney transplantation.
JAMA. 2006 Dec 20;296(23):2823-31
PMID: 17179459
-
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.
Nat Med. 2002 Feb;8(2):128-35
PMID: 11821896
-
Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients.
Transplantation. 2005 Sep 27;80(6):749-58
PMID: 16210961
-
Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.
N Engl J Med. 1999 Dec 2;341(23):1725-30
PMID: 10580071
-
Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies.
Transplantation. 2005 Oct 15;80(7):883-9
PMID: 16249734
-
Malignancy after transplantation.
Transplantation. 2005 Oct 15;80(2 Suppl):S254-64
PMID: 16251858
-
mTOR inhibition and its effect on cancer in transplantation.
Transplantation. 2005 Sep 27;80(1 Suppl):S171-4
PMID: 16286900
-
Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.
J Am Soc Nephrol. 2006 Feb;17(2):581-9
PMID: 16434506
-
Kidneys from deceased donors: maximizing the value of a scarce resource.
Am J Transplant. 2005 Jul;5(7):1725-30
PMID: 15943632
-
Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma.
Transplantation. 2004 Mar 15;77(5):760-2
PMID: 15021843
-
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.
J Clin Oncol. 2004 Mar 1;22(5):909-18
PMID: 14990647